PPIDT00055
Drug Information
| Name | Infliximab |
|---|---|
| Sequence | EVKLEESGGGLVQPGGSMKLSCVASGFIFSNHWMNWVRQSPEKGLEWVAEIRSKSINSATHYAESVKGRFTISRDDSKSAVYLQMTDLRTEDTGVYYCSRNYYGSTYDYWGQGTTLTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDTAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB00065 |
| Type | biotech |
| Indication | Infliximab is indicated for the following conditions: - moderately to severely active ulcerative colitis following treatment with an infliximab product administered intravenously [L51793] - moderately to severely active Crohn’s disease following treatment with an infliximab product administered intravenously [L51793] - use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis. • maintenance treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab. • maintenance treatment of adults with moderately to severely active ulcerative colitis who have had an inadequate response or were intolerant to conventional therapy. Remsima SC should only be used as maintenance therapy after the completion of an induction period with intravenous infliximab. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Powder | Parenteral |
100 MG
|
| Injection, powder, for solution | Intravenous; Parenteral |
100 MG
|
| Injection, powder, lyophilized, for solution | Intravenous |
100 mg/10mL
|
| — | — |
100 mg/1vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
100 mg
|
| Powder | — |
100 mg/1vial
|
| Powder | Intravenous; Parenteral |
100 MG
|
| Powder, for solution | Intravenous |
100 mg / vial
|
| Injection, powder, lyophilized, for solution | Intravenous |
10000000 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg
|
| Injection, powder, for solution | Intravenous |
100 mg
|
| Injection, solution | Parenteral; Subcutaneous |
120 MG
|
| Injection, solution | Subcutaneous |
120 mg
|
| Injection, solution, concentrate | Intravenous |
100 mg/1vial
|
| Solution | Intravenous |
100.000 mg
|
| Injection | Intravenous |
100 mg
|
| Solution | — |
120 mg
|
| Solution | Subcutaneous |
12000000 mg
|
| Kit; solution | Subcutaneous |
120 mg / mL
|
| Solution | Subcutaneous |
120.00 mg
|
| Injection, solution | Subcutaneous |
120 mg/ml
|
| Injection, powder, lyophilized, for suspension | Intravenous |
100 mg
|
| Injection, powder, lyophilized, for solution | Intravenous |
100 mg/1
|
| Injection, powder, for solution | — |
100 mg
|
| Injection | Subcutaneous |
120 mg/1mL
|